Skip to main content

Table 1 Analytes identified that showed variation in measurement performance across blood sample types #

From: Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study

Detectability based on percent of samples > LLOQ

Detected in less than 50% of samples for all three sample types

CCL3, CSF2, FABP3, HSPD1, IL10, IL12A/IL12B, IL17A, IL1B, IL2, IL23B, IL3, IL4, IL5, IL6, IL7, INS_intact, INS_total, LTA, MDA-LDL, MICA, NGF, S100B, TNF

Detected in >50% of serum samples but not in > 50% of EDTA or P100 plasma samples

IL1A, IL1RN, IL12B, OLR1

Detected in >50% of EDTA and P100 plasma samples but not in > 50% of serum samples

FGA_FGB_FGG, IFNG, MMP2

Measurability based on reliability and CV

Reliability values <0.60 or CV (%) ≥ 20 in all three sample types in samples where one or more sample types had >50% of samples > LLOQ.

ALB, CA9, IFNG, IL1RN, IL12B, SPINK1, TIMP1

Performed better* in EDTA plasma compared to serum

ADIPOQ, AGER, ALB$, CCL16, CCL5, CRP, GC, HP, IgM, MMP9, SERPINE1, VEGFA

Perform better & in serum compared to EDTA plasma

ANGPT1, CA9$, CEACAM1, CCL2, CCL20, FAS, HGF, IL18, KITLG, SERPINA3, THBD

Ratio of CV of P100:EDTA plasma > 1.5

ADIPOQ, CXCL9, IL18BP, IgM, PEACAM1, SPINK1$, SFTPD, VEGFA

Ratio of CV of P100:EDTA plasma < 0.667

CCL4

Measured values

Mean levels > 1.5 fold higher in serum compared to plasma

A2M, ANGPT1, BDNF, CCL11, CCL13, CCL2, CCL24, CCL5, HGF, MMP3, LTF, SERPINE1, SFTPD, TGFB1_LAP, TIMP1$, TNFRSF11B, VEGFA

Mean levels > 1.5 fold higher in plasma compared to serum

CDH13, MMP9, SOD1

  1. # When possible, the analytes are identified by the official gene symbol; Refer to Additional file 1: Table S1 for listing of all analyte designations.
  2. *Better performance in EDTA plasma compared to serum is determined when either the ratio of CV serum:CV EDTA plasma >1.5 or the difference in the reliability score for serum minus EDTA plasma < −0.15.
  3. &Better performance in serum compared to EDTA plasma is determined when either the ratio of CV serum:CV plasma <0.667 or the difference in the reliability score for serum minus EDTA plasma >0.15.
  4. $Analytes with this designation had poor measurement characteristics in all three sample types as designated in the table as producing reliability values <0.60 or CV (%) ≥ 20 in all three sample types.